Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab

Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab

Incyte (INCY) and MorphoSys (MOR) have announced that the US Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) plus lenalidomide for adults with relapsed or refractory diffus…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *